The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
Authors
Keywords
Guidelines, Immunotherapy, Prostate Cancer, Treatment
Journal
Journal for ImmunoTherapy of Cancer
Volume 4, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-12-09
DOI
10.1186/s40425-016-0198-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer
- (2016) Cora Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015
- (2016) William T. Lowrance et al. JOURNAL OF UROLOGY
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
- (2015) Peter F. Mulders et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
- (2015) E. J. Small et al. CLINICAL CANCER RESEARCH
- Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
- (2015) D. GuhaThakurta et al. CLINICAL CANCER RESEARCH
- A National Multicenter Phase 2 Study of Prostate-specific Antigen (PSA) Pox Virus Vaccine with Sequential Androgen Ablation Therapy in Patients with PSA Progression: ECOG 9802
- (2015) Robert S. DiPaola et al. EUROPEAN UROLOGY
- Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
- (2015) Charles J Ryan et al. LANCET ONCOLOGY
- Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective
- (2015) Emma L. Simpson et al. PHARMACOECONOMICS
- Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms
- (2015) David I. Quinn et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Randomized phase II trial of docetaxel with or without PSA-TRICOM vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ECOG-ACRIN cancer research group (E1809)
- (2015) Douglas G McNeel et al. Human Vaccines & Immunotherapeutics
- Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications
- (2014) JamesL Gulley et al. ASIAN JOURNAL OF ANDROLOGY
- A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates
- (2014) Caroline Jochems et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- 980 A randomized phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC): Immune results with a focus on humoral responses
- (2014) E.S. Antonarakis et al. EUROPEAN UROLOGY SUPPLEMENTS
- Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline
- (2014) Ethan Basch et al. JOURNAL OF CLINICAL ONCOLOGY
- Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer
- (2014) Lawrence Fong et al. JNCI-Journal of the National Cancer Institute
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis
- (2014) Tobias Engel Ayer Botrel et al. International Braz J Urol
- A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T
- (2014) D. G. McNeel et al. Cancer Immunology Research
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
- (2013) Howard L. Kaufman et al. Nature Reviews Clinical Oncology
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial
- (2013) Paul F. Schellhammer et al. UROLOGY
- DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer
- (2013) Fredrik Eriksson et al. VACCINE
- Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
- (2013) J. L. Gulley et al. Cancer Immunology Research
- Systematic review/Meta-analysis Sipuleucel-T immunotherapy for castration-resistant prostate cancer. A systematic review and meta-analysis
- (2012) Paweł Kawalec et al. Archives of Medical Science
- Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer
- (2012) Nadeem A. Sheikh et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Combination immunotherapy with prostate GVAX and ipilimumab: safety and toxicity
- (2012) Dev Karan et al. Immunotherapy
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- (2012) Karim Fizazi et al. LANCET ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
- (2012) Charles J. Ryan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Response to Sipuleucel-T in Prostate Cancer
- (2012) Eddie Thara et al. Cancers
- Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer
- (2011) T. M. Beer et al. CLINICAL CANCER RESEARCH
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer
- (2009) Douglas G. McNeel et al. JOURNAL OF CLINICAL ONCOLOGY
- Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients
- (2009) Philippe O. Gannon et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Human prostate-infiltrating CD8+T lymphocytes are oligoclonal and PD-1+
- (2009) Karen S. Sfanos et al. PROSTATE
- CD54 is a surrogate marker of antigen presenting cell activation
- (2008) N. A. Sheikh et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started